SCHEMBL25001237

SCHEMBL25001237

CC(=O)NCCc1c[nH]c2c([N+](=O)[O-])cccc12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTNR1A P48039 10/20 0.65
MTNR1B P49286 9/20 0.65
NQO2 P16083 4/20 0.65
MAPT P10636 3/20 0.58
CYP1A2 P05177 2/20 0.57
BLM P54132 2/20 0.57
MEN1 O00255 1/20 0.57
LMNA P02545 1/20 0.57
PKM P14618 1/20 0.57
TSHR P16473 1/20 0.57
CYP2C19 P33261 1/20 0.57
KMT2A Q03164 1/20 0.57
CDK2 P24941 1/20 0.49
DNA2 P51530 1/20 0.49
CASP6 P55212 1/20 0.49
CTDSP1 Q9GZU7 1/20 0.49
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30580934 1.00 MTNR1A (0.65) MTNR1AMTNR1BNQO2MAPTCYP1A2
SCHEMBL14907362 0.82 MTNR1A (0.72) MTNR1AMTNR1BMAPTCYP1A2BLM
SCHEMBL30733593 0.81 MTNR1A (0.72) MTNR1AMTNR1BNQO2MAPTCYP1A2
SCHEMBL25383376 0.81 MTNR1A (0.72) MTNR1AMTNR1BNQO2MAPTCYP1A2
SCHEMBL6920054 0.81 MTNR1A (0.70) MTNR1AMTNR1BMAPTCYP1A2BLM
SCHEMBL25001887 0.81 MTNR1A (0.56) MTNR1AMTNR1BNQO2MAPTCYP1A2
SCHEMBL28964528 0.80 DNA2 (0.53) MTNR1AMTNR1BNQO2MAPTCDK2
SCHEMBL26285862 0.80 MTNR1A (0.69) MTNR1AMTNR1BMAPTCYP1A2BLM
SCHEMBL26451462 0.80 MTNR1A (0.69) MTNR1AMTNR1BNQO2MAPTCYP1A2
SCHEMBL17108188 0.79 MTNR1A (1.00) MTNR1AMTNR1BNQO2CYP1A2BLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116782896-A Nitrifying galectin derivatives and their use for modulating 5-HT2A receptors and treating psychotic disorders 恩维瑞克生物科学加拿大公司 2023-09-19 CN disclosed
EP-4208446-A1 NITRATED PSILOCYBIN DERIVATIVES AND USE THEREOF FOR MODULATING 5-HT2A RECEPTOR AND FOR TREATING A PSYCHIATRIC DISORDER Enveric Biosciences Canada Inc. (CA) 2023-07-12 EP disclosed
US-20230040398-A1 NITRATED PSILOCYBIN DERIVATIVES AND METHODS OF USING Enveric Biosciences Canada Inc. (CA) 2023-02-09 US disclosed
US-20230040398-A1 NITRATED PSILOCYBIN DERIVATIVES AND METHODS OF USING Enveric Biosciences Canada Inc. (CA) 2023-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230040398-A1 NITRATED PSILOCYBIN DERIVATIVES AND METHODS OF USING PNMT, CNR2, NOS2 MTNR1A 939/4885MTNR1B 162/4885NQO2 347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.